Serum Krebs von den Lungen‐6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients

Hu, Yang; Wang, Liu-Sheng; Jin, Yueping; Du, Shan-Shan; Du, Yuxuan; He, Xiaowen; Wu, Dong; Zhou, Ying; Li, Qiuhong; Shen, Li; Zhang, Fen; Su, Yucai; Sun, Xiaoli; Ding, Jingjing; Zhang, Wenhui; Cai, Hourong; Dai, Huaping; Dai, Jinghong; Li, Huiping

doi:10.1111/crj.12341

Cited by 50 publications

(55 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As we know, ethnicity differences existed in the clinical manifestations and laboratory results of SSc . To our best knowledge, there was only one study from a Chinese cohort retrieved in Pubmed that probed into the correlation between serum KL‐6 and patients with ILD, and they confirmed the diagnosis value of KL‐6 for ILD patients . Our present cohort was intended to investigate the predictive and prognostic value of serum KL‐6 for Chinese SSc‐ILD patients.…”

Section: Introductionmentioning

confidence: 89%

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort

Cao

et al. 2018

Int J of Rheum Dis

View full text Add to dashboard Cite

Aim A prospective and longitudinal study to investigate the correlations between Krebs von den Lungen‐6 (KL‐6) serum levels and systemic sclerosis associated with interstitial lung disease (SSc‐ILD). Method Blood samples of baseline and the time point at 2 years follow‐up intervals were collected for the measurement of serum KL‐6 levels. The baseline clinical, laboratory characteristics, and incidence density of newly diagnosed ILD during the follow up were compared between SSc patients with elevated serum KL‐6 levels (KL‐6 > 500 U/mL) and those with normal KL‐6 levels (KL‐6 ≤ 500 U/mL) at baseline. Further, we explored the association between serum KL‐6 and deterioration of ILD measured by lung function parameters during follow‐up of 2 years. Results Patients with elevated baseline serum KL‐6 had a significant tendency to have disappearance of the finger pad. The incidence density of new‐onset ILD in SSc patients with elevated baseline serum KL‐6 and those with normal baseline serum KL‐6 was 1.33% and 0.51%, respectively. Among the mild lung injury group, the incidence density of ILD deterioration in SSc patients with elevated baseline serum KL‐6 and those with normal serum KL‐6 was 1.2% and 0.74%, respectively. Conclusion Serum KL‐6 level correlates with the clinical manifestations of microvascular injury. Baseline elevated serum KL‐6 may predict deterioration of lung function of SSc‐ILD patients with mild lung injury.

show abstract

Section: Introductionmentioning

confidence: 89%

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort

Cao

et al. 2018

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…indicators. Since this is a noninvasive test, KL-6 test has high clinical application value.Hu et al17 reported that, in China, when the cutoff value was set to 500 U/mL, the sensitivity and specificity of KL-6 in ILD diagnosis were 77.75% and 94.51%, respectively. However, recently, literature reports have shown that the cutoff value of serum KL-6 level varies among different races 18,19.…”

mentioning

confidence: 99%

Evaluation of the clinical performance of the HISCL‐5000 analyzer in the detection of Krebs von den Lungen‐6 antigen and its diagnostic value in interstitial lung disease

Wang

Huang

Xue

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background The sputum saccharide chain antigen (Krebs von den Lungen‐6 [KL‐6]) is a serum biomarker of lung injury. We aimed to evaluate the clinical performance of the automated immunoassay analyzer HISCL‐5000 in detecting KL‐6 by comparing it with LUMIPULSE G1200 and determine the diagnostic value of KL‐6 in interstitial lung disease (ILD). Methods A total of 145 serum samples from patients were tested using the two automated immunoassay analyzers in parallel. Results With a cutoff level of 500 U/mL, comparing the two systems, the agreement, sensitivity, specificity, and kappa value were 99.20%, 100%, 98.63%, and 0.984 (95% CI, 0.952‐1.000), respectively. Spearman's correlation and ICC showed that there was a strong correlation between serum KL‐6 levels measured by the two systems (rS = .991 [95% CI, 0.981‐0.995], ICC = 0.984 [95% CI, 0.978‐0.989], P < .01). The clinical diagnosis agreement rate in both systems was >80%. The kappa value was 0.707 (95% CI, 0.582‐0.832; SYSTEM B) and 0.707 (95% CI, 0.588‐0.826; SYSTEM A). The KL‐6 level in the ILD group (1339.5, 662.5‐2363) was significantly higher than that in the non‐ILD groups (252, 158.5‐353; Mann‐Whitney U = 381.5, P < .01), and the KL‐6 level (1558, 726‐2772.5) in the ILD group detected by SYSTEM A was significantly higher than that in the lung cancer group (339, 207‐424), other respiratory disease group (249, 194‐366), and control group (198, 131.5‐297; Kruskal‐Wallis H = 63.19, P < .01). Conclusions HISCL‐5000 showed well‐concordant results with those of HISCL‐5000 in the KL‐6 tests. In patients with ILD, KL‐6 showed a good diagnostic performance.

show abstract

“…Serum KL-6 düzeyinin ‹AH'I olan hastalarda olmayanlara göre daha yüksek oldu¤u gösterilmifltir. [49] ‹AH tan›s› koymak için akci¤er biyopsisi yapmaya gerek yoktur. Ancak radyolojik bulgular tipik de¤ilse veya malignite, enfeksiyon, meslek hastal›¤› gibi nedenleri ekarte etmek için yap›labilir.Transbronflial biyopsi de ‹AH tan›s› için flart de¤il fakat ilaç iliflkili akci¤er hasar›, sarkoidoz ya da enfeksiyonu d›fllamak için yap›lmas› gerekebilir.…”

Section: Risk Faktörleriunclassified

Rheumatoid arthritis-associated interstitial lung disease

Beş¹

2015

RAED Derg

View full text Add to dashboard Cite

Serum Krebs von den Lungen‐6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients

Abstract: Serum KL-6 levels might be a promising diagnostic biomarker for ILDs in Chinese patients. The prognostic value of serum KL-6 levels for ILDs remains to be verified by large-scaled studies.

Cited by 50 publications

References 30 publications

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort

Serum levels of Krebs von den Lungen‐6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis‐associated interstitial lung disease from a Chinese cohort

Evaluation of the clinical performance of the HISCL‐5000 analyzer in the detection of Krebs von den Lungen‐6 antigen and its diagnostic value in interstitial lung disease

Rheumatoid arthritis-associated interstitial lung disease

Contact Info

Product

Resources

About